BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 22508966)

  • 1. The CDK4/6 inhibitor PD0332991 reverses epithelial dysplasia associated with abnormal activation of the cyclin-CDK-Rb pathway.
    Cabrera MC; Díaz-Cruz ES; Kallakury BV; Pishvaian MJ; Grubbs CJ; Muccio DD; Furth PA
    Cancer Prev Res (Phila); 2012 Jun; 5(6):810-21. PubMed ID: 22508966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes.
    Paternot S; Colleoni B; Bisteau X; Roger PP
    Cell Cycle; 2014; 13(18):2879-88. PubMed ID: 25486476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.
    Cen L; Carlson BL; Schroeder MA; Ostrem JL; Kitange GJ; Mladek AC; Fink SR; Decker PA; Wu W; Kim JS; Waldman T; Jenkins RB; Sarkaria JN
    Neuro Oncol; 2012 Jul; 14(7):870-81. PubMed ID: 22711607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of retinoblastoma protein and D cyclins during cell-growth inhibition by hexamethylenebisacetamide in TM2H mouse epithelial cells.
    Said TK; Medina D
    Mol Carcinog; 1998 Jun; 22(2):128-43. PubMed ID: 9655257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for a CDK4-dependent checkpoint in a conditional model of cellular senescence.
    Brookes S; Gagrica S; Sanij E; Rowe J; Gregory FJ; Hara E; Peters G
    Cell Cycle; 2015; 14(8):1164-73. PubMed ID: 25695870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia.
    Wang L; Wang J; Blaser BW; Duchemin AM; Kusewitt DF; Liu T; Caligiuri MA; Briesewitz R
    Blood; 2007 Sep; 110(6):2075-83. PubMed ID: 17537993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy.
    Roberts PJ; Bisi JE; Strum JC; Combest AJ; Darr DB; Usary JE; Zamboni WC; Wong KK; Perou CM; Sharpless NE
    J Natl Cancer Inst; 2012 Mar; 104(6):476-87. PubMed ID: 22302033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity.
    Lukas J; Bartkova J; Rohde M; Strauss M; Bartek J
    Mol Cell Biol; 1995 May; 15(5):2600-11. PubMed ID: 7739541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
    Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
    Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attenuation of the retinoblastoma pathway in pancreatic neuroendocrine tumors due to increased cdk4/cdk6.
    Tang LH; Contractor T; Clausen R; Klimstra DS; Du YC; Allen PJ; Brennan MF; Levine AJ; Harris CR
    Clin Cancer Res; 2012 Sep; 18(17):4612-20. PubMed ID: 22761470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of cell cycle regulators in tumor formation in transgenic mice expressing the human neurotropic virus, JCV, early protein.
    Krynska B; Gordon J; Otte J; Franks R; Knobler R; DeLuca A; Giordano A; Khalili K
    J Cell Biochem; 1997 Nov; 67(2):223-30. PubMed ID: 9328827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells.
    Rivadeneira DB; Mayhew CN; Thangavel C; Sotillo E; Reed CA; Graña X; Knudsen ES
    Gastroenterology; 2010 May; 138(5):1920-30. PubMed ID: 20100483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma.
    Ely S; Di Liberto M; Niesvizky R; Baughn LB; Cho HJ; Hatada EN; Knowles DM; Lane J; Chen-Kiang S
    Cancer Res; 2005 Dec; 65(24):11345-53. PubMed ID: 16357141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia.
    Nemoto A; Saida S; Kato I; Kikuchi J; Furukawa Y; Maeda Y; Akahane K; Honna-Oshiro H; Goi K; Kagami K; Kimura S; Sato Y; Okabe S; Niwa A; Watanabe K; Nakahata T; Heike T; Sugita K; Inukai T
    Mol Cancer Ther; 2016 Jan; 15(1):94-105. PubMed ID: 26637365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Molecular mechanisms controlling the cell cycle: fundamental aspects and implications for oncology].
    Viallard JF; Lacombe F; Belloc F; Pellegrin JL; Reiffers J
    Cancer Radiother; 2001 Apr; 5(2):109-29. PubMed ID: 11355576
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p18Ink4c and p53 Act as tumor suppressors in cyclin D1-driven primitive neuroectodermal tumor.
    Saab R; Rodriguez-Galindo C; Matmati K; Rehg JE; Baumer SH; Khoury JD; Billups C; Neale G; Helton KJ; Skapek SX
    Cancer Res; 2009 Jan; 69(2):440-8. PubMed ID: 19147556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TGF-beta-mediated cell cycle arrest of HPV16-immortalized human ectocervical cells correlates with decreased E6/E7 mRNA and increased p53 and p21(WAF-1) expression.
    Rorke EA; Zhang D; Choo CK; Eckert RL; Jacobberger JW
    Exp Cell Res; 2000 Aug; 259(1):149-57. PubMed ID: 10942587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D:Cdk4/6 complexes results in active pRb.
    Ezhevsky SA; Nagahara H; Vocero-Akbani AM; Gius DR; Wei MC; Dowdy SF
    Proc Natl Acad Sci U S A; 1997 Sep; 94(20):10699-704. PubMed ID: 9380698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of cyclin D1 alters cdk 4- and cdk 2-specific phosphorylation of retinoblastoma protein.
    Yu B; Lane ME; Pestell RG; Albanese C; Wadler S
    Mol Cell Biol Res Commun; 2000 Jun; 3(6):352-9. PubMed ID: 11032757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p16/p14(ARF) cell cycle regulatory pathways in primary neuroblastoma: p16 expression is associated with advanced stage disease.
    Omura-Minamisawa M; Diccianni MB; Chang RC; Batova A; Bridgeman LJ; Schiff J; Cohn SL; London WB; Yu AL
    Clin Cancer Res; 2001 Nov; 7(11):3481-90. PubMed ID: 11705866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.